Rationale, design, and baseline characteristics in evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Rhonda Bentley-Lewis, David Aguilar, Matthew C. Riddle, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C. Gerstein, Peter Johnston, Lars V. Køber, Francesca Lawson, Eldrin F. Lewis, Aldo P. Maggioni, John J. V. McMurray, Lin Ping, Jeffrey L. Probstfield, Scott D. Solomon, Jean-Claude Tardif, Yujun Wu, Marc A. Pfeffer, ELIXA InvestigatorsChristian Torp-Pedersen

Research output: Contribution to journalJournal articleResearchpeer-review

68 Citations (Scopus)
Original languageEnglish
JournalAmerican Heart Journal
Volume169
Issue number5
Pages (from-to)631-638.e7
Number of pages15
ISSN0002-8703
DOIs
Publication statusPublished - 2015

Cite this

Bentley-Lewis, R., Aguilar, D., Riddle, M. C., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Johnston, P., Køber, L. V., Lawson, F., Lewis, E. F., Maggioni, A. P., McMurray, J. J. V., Ping, L., Probstfield, J. L., Solomon, S. D., Tardif, J-C., Wu, Y., Pfeffer, M. A., ... Torp-Pedersen, C. (2015). Rationale, design, and baseline characteristics in evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 169(5), 631-638.e7. https://doi.org/10.1016/j.ahj.2015.02.002